Koga S, Maeta M, Wakatsuki T, Ikeda Y, Inoue Y, Ishiguro M
Gan To Kagaku Ryoho. 1987 Feb;14(2):404-10.
Eight hepatocellular cancer patients and eighteen metastatic liver cancer patients were treated with intrahepato-arterial infusion of CDDP (cis-diamminedichloro-platinum II) plus 5-FU (5-fluorouracil); CDDP (0.8-1.0 mg/kg) was given once every 7 or 10-14 days, while 5-FU (250-100 mg/day) was infused daily. A partial response was obtained in 5 of 8 patients with primary liver cancer and in 9 of 14 evaluable patients with metastatic liver cancer. However, severe complications due to bone marrow suppression were observed in 4 patients, 3 of whom died of septicemia and one of enterocolitis. This combined intra-hepato-arterial chemotherapy exerts a synergistic anticancer effect on malignant liver tumors, although the bone marrow suppression associated with it remains to be overcome.
8例肝细胞癌患者和18例转移性肝癌患者接受了肝动脉内输注顺铂（顺二氨二氯铂II）加5-氟尿嘧啶（5-FU）的治疗；顺铂（0.8-1.0mg/kg）每7天或10-14天给药一次，而5-氟尿嘧啶（250-100mg/天）每天输注。8例原发性肝癌患者中有5例、14例可评估的转移性肝癌患者中有9例获得了部分缓解。然而，4例患者出现了严重的骨髓抑制并发症，其中3例死于败血症，1例死于小肠结肠炎。这种联合肝动脉内化疗对恶性肝肿瘤具有协同抗癌作用，尽管与之相关的骨髓抑制仍有待克服。
